Patent – Validity. The Supreme Court was divided on the question how the concepts of sufficiency and infringement were to be applied to a patent relating to a specified medical use of a known pharmaceutical compound, particularly Swiss-form patents, in proceedings raising those issues for the first time in the UK courts. However, the majority, in dismissing Warner-Lambert Company LLC's appeal, and allowing Mylan and Actavis Group PTC EHF's cross-appeal, held that the patent claims were invalid for insufficiency, as the disclosure had not contributed any knowledge of the art capable of justifying a claim to a monopoly.